Compare Illinois Tool Works Inc. (ITW) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Nuvalent Inc — how do they compare? Illinois Tool Works Inc. trades at $271.88 (market cap $78.17B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Illinois Tool Works Inc. is far larger — about 8× Nuvalent Inc's market cap, and Illinois Tool Works Inc. pays a 2.37% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| ITW | NUVL | |
|---|---|---|
Market Cap | $78.17B | $9.81B |
Sector | Industrials | Technology |
52-Week High | $299.60 | $123.96 |
52-Week Low | $241.07 | $72.16 |
Enterprise Value | $86.49B | $8.52B |
Dividend Yield | 2.37% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
